SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 52-Week High – Should You Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $15.88 and last traded at $14.76, with a volume of 21504395 shares traded. The stock had previously closed at $15.45.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on SLS shares. Maxim Group raised their target price on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Stock Down 4.5%

The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of -64.17 and a beta of 2.50. The stock has a fifty day moving average price of $7.54 and a two-hundred day moving average price of $5.36.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Hedge funds have recently modified their holdings of the company. Larson Financial Group LLC acquired a new position in shares of SELLAS Life Sciences Group in the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets boosted its position in SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after acquiring an additional 9,299 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in SELLAS Life Sciences Group during the fourth quarter worth approximately $38,000. Beacon Pointe Advisors LLC purchased a new stake in SELLAS Life Sciences Group in the 4th quarter worth approximately $38,000. Finally, California State Teachers Retirement System grew its stake in SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after acquiring an additional 1,709 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.